News Releases

 
Vexim lists on NYSE Alternext
Paris, 3 May 2012 – NYSE Euronext today announced the listing on NYSE Alternext in Paris of Vexim, a key player in innovative microsurgery for spinal trauma.

Founded in 2006 and based in Toulouse, Vexim specialises in minimally invasive treatment of vertebral compression fractures and has designed and developed SpineJack®, which it markets. This innovative technology consists of a 5-mm titanium implant that restores the crushed vertebrae’s initial height, volume and natural anatomy, and eliminates pain. The company currently employs 27 people and has an extensive distribution network in France and Germany.

Vexim (ticker code: ALVXM) was listed through admission to trading of 2,163,100 existing shares and 1,158,544 new shares issued under a Global Offering.[1]The Global Offering raised a total of €11 million.

The admission and issue price of Vexim shares was set at €9.50. Market capitalization stood at around €31.6 million on the day of listing.

“We are delighted to welcome Toulouse-based Vexim to NYSE Alternext. Listing is a new and important stage in its growth that will consolidate its reputation and raise the funds it needs to pursue investment in R&D,” said Marc Lefèvre, Head of European Coverage at NYSE Euronext. “NYSE Alternext is a perfect match for companies like Vexim that want to benefit from our European reach which attracts a rising number of investors and higher liquidity.”

Vincent Gardès, CEO of Vexim, added: “We would like to thank all of the shareholders that have placed their trust in us and made this critical step a success, and who are now on board as we pursue our commercial development.”

In seven years, €2.7 billion has been raised on NYSE Alternext, half through secondary issues, by companies from countries including Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Their market capitalisation totals €6.2 billion. Today 183 companies are listed on NYSE Alternext.


[1]The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

Press contacts:

NYSE Euronext                                                                                                
Caroline Tourrier: +33 (0)1 49 27 10 82 – ctourrier@nyx.com

Vexim
NewCap.
Dusan Oresansky / Emmanuel Huynh: +33 (0)1 44 71 94 92 –
vexim@newcap.fr          

Alize RP
Caroline Carrmagnol: +33 (0)6 64 18 99 59 – caroline@alizerp.com
Anne-Sophie
Cosquéric: +33 (0)1 42 68 86 41 – anne-sophie@alizerp.com

About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets — the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca — represent one-third of the worlds equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the Fortune 500. For more information, please visit: www.nyx.com.

About Vexim
Based in Balma, near Toulouse in southwestern France, Vexim is a medical device company set up in February 2006 following the spin-off of research at Teknimed, a world leader in bone substitutes and surgical cement. Vexim specialises in developing and marketing minimally invasive solutions for the treatment of spinal trauma. Backed by its longstanding shareholders Truffle Capital and Banexi Venture, plus funding from state-owned Oseo, Vexim designed and now markets SpineJack®, a unique implant capable of restoring a fractured vertebrae’s initial form and thus rebalancing the anatomy of the backbone. The company current has 27 employees. It also has its own sales team in France and in Germany, and distributors in Spain, Portugal, Italy, Turkey, Argentina and South Africa. For more information, visit www.vexim.com.